檢索結果 - Haihong Shi

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of <scp>COVID</scp>‐19, in Subjects With Renal Impairment

    Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of <scp>COVID</scp>‐19, in Subjects With Renal Impairment 由 Sima S. Toussi, Joel M. Neutel, J. Navarro, Richard Alfred Preston, Haihong Shi, Olga Kavetska, Robert R. LaBadie, Michael Binks, Phylinda L. Chan, Neil Demers, Brian Corrigan, Bharat Damle

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

    Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir 由 Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, Phylinda L. Chan, Rohit Rao, Richard Allen, Lien Van Eyck, Sylvester Pawlak, Eugene P. Kadar, Frances Clark, Haihong Shi, Annaliesa S. Anderson, Michael Binks, Sandeep Menon, Gianluca Nucci, Arthur Bergman

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: